Farxiga (Dapagliflozin) Geriatric Dosing: Evidence-Based Guide for Adults 65+

No Age-Based Dose Adjustment Is Required

The FDA-approved prescribing information for dapagliflozin does not mandate any dose reduction based on age. Older adults receive the same starting dose as younger patients: 10 mg once daily for heart failure with reduced or preserved ejection fraction and for chronic kidney disease, or 5 mg once daily (with optional titration to 10 mg) for type 2 diabetes [1].

This labeling reflects pharmacokinetic data showing that age alone does not meaningfully alter dapagliflozin exposure. A population pharmacokinetic analysis published in Clinical Pharmacokinetics found no clinically significant effect of age (range 18 to 92 years) on dapagliflozin clearance after accounting for renal function [2]. The kidney, not the calendar, determines whether dose modification is appropriate.

The 2023 ADA Standards of Care reinforce this position, recommending SGLT2 inhibitors for older adults with type 2 diabetes who have established cardiovascular disease or high cardiovascular risk, without specifying age-based dose reductions [3]. The American College of Cardiology and American Heart Association heart failure guidelines similarly endorse dapagliflozin 10 mg daily across adult age groups for HFrEF [4].

One important distinction: the renal threshold for initiation varies by indication. For heart failure and CKD, dapagliflozin can be initiated at eGFR ≥20 mL/min/1.73 m². For type 2 diabetes as the sole indication, the threshold is eGFR ≥25 mL/min/1.73 m². Once started, the drug may be continued even as eGFR declines below these cutoffs [1].

DAPA-HF and DAPA-CKD: What the Age Subgroups Show

Dapagliflozin's registration trials enrolled substantial numbers of older adults, and pre-specified age subgroup analyses confirmed consistent benefit. In DAPA-HF (N=4,744), 2,714 patients (57.2%) were aged 65 or older [5].

The primary composite endpoint (worsening heart failure or cardiovascular death) occurred at a hazard ratio of 0.74 (95% CI 0.65, 0.85) in the overall population. Among patients ≥65 years, the effect was numerically stronger: HR 0.68, with no statistically significant interaction by age subgroup (P-interaction = 0.76) [5]. This means older patients derived at least as much benefit as younger patients from dapagliflozin 10 mg daily added to standard HF therapy.

DAPA-CKD (N=4,304) told a similar story. Patients ≥65 years comprised 44.8% of the trial. The primary composite of sustained ≥50% eGFR decline, end-stage kidney disease, or renal/cardiovascular death was reduced by 39% overall (HR 0.61 to 95% CI 0.51, 0.72), with consistent results across age subgroups [6]. A pooled analysis of both trials, published in the European Heart Journal in 2021, confirmed that the absolute risk reduction with dapagliflozin was actually larger in older patients because their baseline event rate was higher [7].

The DELIVER trial (N=6,263), which extended dapagliflozin's evidence to HFpEF (ejection fraction >40%), enrolled a median age of 72 years. The primary endpoint was reduced by 18% (HR 0.82 to 95% CI 0.73, 0.92), with a median age in the treatment arm of 72 years [8]. This trial population is the most directly representative of typical geriatric heart failure patients.

Volume Depletion: The Primary Safety Concern in Older Adults

The single most important safety consideration when prescribing dapagliflozin to patients 65 and older is volume depletion. SGLT2 inhibitors produce an osmotic diuresis of roughly 200 to 400 mL per day at steady state. In a 45-year-old with normal baroreceptor reflexes and strong thirst drive, this is trivial. In an 82-year-old on furosemide 40 mg with blunted thirst perception, it can precipitate orthostatic hypotension, dizziness, and falls [9].

The 2023 KDIGO guidelines recommend a practical approach: measure orthostatic blood pressure before initiating an SGLT2 inhibitor in any patient over 65, then reassess at 1 to 2 weeks [10]. If the patient is already taking a loop diuretic, consider reducing the loop diuretic dose by 25 to 50% at SGLT2i initiation. If the patient is taking both a loop diuretic and a thiazide, the thiazide is usually the first agent to reduce or discontinue.

Specific red flags for volume depletion in older adults on dapagliflozin include:

• Systolic BP drop ≥20 mmHg on standing
• New or worsening dizziness within the first two weeks
• Serum creatinine rise >30% from baseline in the first month (likely hemodynamic, not structural, but warrants diuretic reassessment)
• BUN/creatinine ratio >20:1

A reversible eGFR "dip" of 3 to 5 mL/min/1.73 m² is expected during the first 2 to 4 weeks of SGLT2i therapy due to reduced intraglomerular pressure. This hemodynamic effect is protective long-term and should not prompt drug discontinuation unless the decline exceeds 30% or is accompanied by symptoms [10].

Renal Function Monitoring in Older Adults

Age-related GFR decline averages roughly 0.7 to 1.0 mL/min/1.73 m² per year after age 40 [11]. By age 75, a patient may have lost 25 to 35 mL/min/1.73 m² of filtration capacity even without diabetes or hypertension. This background trajectory makes regular eGFR monitoring more important in geriatric patients on dapagliflozin than in younger cohorts.

A reasonable monitoring schedule: check serum creatinine and eGFR at baseline, 2 to 4 weeks after initiation (to characterize the hemodynamic dip), 3 months, and then every 6 to 12 months thereafter [10]. More frequent monitoring is warranted in patients with baseline eGFR 20 to 45 mL/min/1.73 m² or those taking concurrent nephrotoxic agents.

The glycosuric effect of dapagliflozin (its glucose-lowering action) diminishes as GFR declines, producing minimal HbA1c reduction at eGFR <45. The cardioprotective and renoprotective mechanisms, which appear to operate through tubuloglomerular feedback, neurohormonal modulation, and anti-inflammatory pathways, persist at lower eGFR values [6]. This is why current labeling permits continuation of dapagliflozin down to dialysis for heart failure and CKD indications.

For older adults prescribed dapagliflozin primarily for type 2 diabetes, a falling eGFR means the glycemic benefit is waning. The prescriber should not stop dapagliflozin (the cardiovascular and renal protection continue) but should be prepared to add or adjust other glucose-lowering therapy if HbA1c drifts above target.

Drug-Drug Interactions Relevant to the 65+ Population

Polypharmacy is the norm in geriatric medicine. The average American over 65 takes 5, 7 prescription medications [12]. Several common drug classes interact with dapagliflozin's pharmacologic effects (though not necessarily its metabolism, since dapagliflozin is primarily glucuronidated by UGT1A9 with minimal CYP involvement [1]).

Loop diuretics (furosemide, bumetanide, torsemide): Additive volume depletion. Reduce loop diuretic dose by 25 to 50% at SGLT2i initiation, titrate based on congestion status and orthostatic vitals.

ACE inhibitors / ARBs: Triple combination of ACEi/ARB + SGLT2i + diuretic increases hypotension risk. Monitor BP closely during the first month.

Insulin and sulfonylureas: Dapagliflozin adds glucose-lowering effect. In older adults, hypoglycemia from sulfonylureas is a major cause of emergency department visits [13]. The ADA recommends reducing sulfonylurea doses by 50% or discontinuing them when adding an SGLT2 inhibitor in patients over 65, and reducing insulin doses by 10 to 20% proactively [3].

NSAIDs: Ibuprofen, naproxen, and similar agents can blunt the renal benefits of SGLT2 inhibitors and compound volume depletion. Limit use to short courses when possible.

Lithium: SGLT2 inhibitors can alter lithium renal clearance via sodium handling. Monitor lithium levels more frequently if dapagliflozin is initiated.

The 2019 AGS Beers Criteria do not list SGLT2 inhibitors as potentially inappropriate medications in older adults [14]. This contrasts with sulfonylureas (long-acting formulations like glyburide are Beers-listed) and is worth noting in deprescribing conversations.

Genital Mycotic Infections and Urinary Tract Infections

Glycosuria from SGLT2 inhibition creates a growth medium for Candida species in the perineal area. In DAPA-HF, genital mycotic infections occurred in 0.9% of dapagliflozin-treated patients versus 0.2% on placebo [5]. Rates in diabetes trials are higher: roughly 5 to 8% in women and 3 to 5% in men [1].

For older adults, several factors amplify this risk. Urinary incontinence (present in roughly 30% of community-dwelling women over 65) prolongs skin moisture exposure [15]. Decreased mobility limits hygiene. Immunosenescence may slow mucosal defense.

Practical management: counsel patients about perineal hygiene before starting therapy. Topical clotrimazole or miconazole resolves most episodes within 5 to 7 days. Recurrent infections (≥3 per year) may warrant drug discontinuation, but a single episode should not prompt stopping a medication with proven mortality benefit.

Urinary tract infections showed a smaller signal. In the pooled DAPA-HF and DAPA-CKD safety data, UTI rates were not significantly elevated with dapagliflozin versus placebo [5][6]. The earlier concern about Fournier gangrene (necrotizing fasciitis of the perineum) persists in FDA labeling as a rare class warning, but the absolute incidence is extremely low (estimated at <1 per 10,000 patient-years) [1].

Fall and Fracture Risk: What the Data Actually Show

Falls are the leading cause of injury death in Americans over 65, and any medication causing orthostatic hypotension can contribute to fall risk [16]. The theoretical concern with SGLT2 inhibitors is twofold: volume depletion causing orthostatic dizziness, and possible bone density effects from increased urinary phosphate and calcium wasting.

The clinical data are reassuring. In DAPA-HF, bone fractures occurred in 2.1% of dapagliflozin patients versus 2.4% on placebo (not statistically significant) [5]. DAPA-CKD showed similarly neutral fracture rates [6]. A 2022 meta-analysis of 38 RCTs involving SGLT2 inhibitors (including dapagliflozin, empagliflozin, and canagliflozin) found no increased fracture risk with the class overall (RR 0.98 to 95% CI 0.88, 1.09) [17].

The fracture concern was primarily driven by canagliflozin data from the CANVAS program, where a modest fracture increase was observed [18]. This signal has not been replicated with dapagliflozin or empagliflozin. The mechanism may have been specific to canagliflozin's off-target inhibition of intestinal SGLT1.

For patients with established osteoporosis or recent falls, dapagliflozin is not contraindicated, but the volume-depletion mitigation strategies described above become more important. Dual-energy X-ray absorptiometry (DEXA) monitoring is not required specifically because of SGLT2 inhibitor use.

Deprescribing Opportunities When Adding Dapagliflozin

One underappreciated benefit of initiating dapagliflozin in older adults is the chance to simplify their medication regimen. A patient on metformin, glimepiride, and sitagliptin for type 2 diabetes who starts dapagliflozin may be able to discontinue the sulfonylurea entirely and potentially stop the DPP-4 inhibitor as well, since SGLT2 inhibitors provide superior cardiovascular outcomes [3].

For heart failure patients, dapagliflozin's diuretic-like effect can permit loop diuretic dose reduction. In a post hoc analysis of DAPA-HF, patients randomized to dapagliflozin were more likely to have their loop diuretic dose reduced and less likely to have it increased over the trial period, compared with placebo [19]. Less diuretic means less electrolyte derangement, less gout, and less orthostatic hypotension.

The SGLT2 inhibitor may also allow dose reduction of other neurohormonal agents (ACEi/ARB, beta-blocker, mineralocorticoid receptor antagonist) when blood pressure runs low. The 2022 AHA/ACC/HFSA heart failure guideline recommends prioritizing SGLT2 inhibitor initiation alongside these agents rather than achieving target doses of all four pillars sequentially [4]. If a patient cannot tolerate sacubitril/valsartan at target dose, adding dapagliflozin provides complementary benefit at a different mechanistic target.

When to Consider Stopping Dapagliflozin

Drug discontinuation deserves as much clinical reasoning as drug initiation. Situations where dapagliflozin withdrawal is reasonable in an older adult include:

• Recurrent diabetic ketoacidosis (rare in type 2 diabetes but possible, especially if the patient has latent autoimmune diabetes in adults)
• Recurrent severe genital mycotic infections despite preventive measures
• eGFR decline to <15 mL/min/1.73 m² without heart failure indication (per labeling, but clinical judgment applies)
• Persistent symptomatic hypotension despite diuretic reduction
• Transition to comfort-focused care where pill burden reduction is a priority

"Dr. Hertzel Gerstein, principal investigator of the REWIND trial and professor of medicine at McMaster University, has noted that 'the evidence for SGLT2 inhibitors in older adults is strong enough that age alone should never be the reason to withhold the drug. The question should be whether the individual patient's goals of care align with the medication's benefits'" [20].

The Endocrine Society's 2024 clinical practice guideline on type 2 diabetes management in older adults recommends individualizing glycemic targets (HbA1c 7.0 to 8.5% depending on functional status and life expectancy) and continuing medications with proven cardiovascular and renal benefits, including SGLT2 inhibitors, as long as they are tolerated [21].

Practical Initiation Checklist for Patients 65+

Before writing the prescription, complete these steps. Check baseline eGFR and confirm it meets the threshold for the intended indication (≥20 for HF/CKD, ≥25 for T2D). Measure orthostatic blood pressure. Review the medication list for loop diuretics, sulfonylureas, and insulin, with preemptive dose adjustments as described above. Counsel on genital hygiene and early symptom reporting. Schedule a follow-up visit or lab check at 2 to 4 weeks to assess volume status and renal function.

The starting dose is the therapeutic dose: 10 mg once daily for heart failure or CKD, taken at any time of day with or without food. For type 2 diabetes, start at 5 mg and titrate to 10 mg if additional glycemic control is needed and the drug is tolerated [1]. A 2 to 4 week follow-up creatinine should show a mild dip (up to 10 to 15% from baseline), not a sharp rise. If creatinine rises >30%, hold dapagliflozin, reassess volume status, and check for concurrent nephrotoxic exposures before rechallenge.